Oscar Health (NYSE:OSCR) Trading Down 5.2% – What’s Next?

Oscar Health, Inc. (NYSE:OSCR) shares fell 5.2% on Friday . The stock traded as low as $16.03 and last traded at $16.31. 458,559 shares were traded during trading, a decline of 86% from the average session volume of 3,191,652 shares. The stock had previously closed at $17.20.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. UBS Group began coverage on Oscar Health in a report on Monday, October 7th. They issued a “neutral” rating and a $23.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 price target on shares of Oscar Health in a research note on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Oscar Health presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Oscar Health Trading Down 5.9 %

The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $18.80 and a two-hundred day moving average price of $18.35. The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of -40.48, a PEG ratio of 31.76 and a beta of 1.62.

Oscar Health (NYSE:OSCR) last issued its earnings results on Wednesday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.04. Oscar Health had a return on equity of 1.86% and a net margin of 0.25%. The company had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the prior year, the business earned ($0.07) EPS. The firm’s quarterly revenue was up 44.6% on a year-over-year basis. As a group, research analysts forecast that Oscar Health, Inc. will post 0.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Alessandrea C. Quane sold 16,793 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $17.06, for a total value of $286,488.58. Following the transaction, the executive vice president now directly owns 392,607 shares in the company, valued at approximately $6,697,875.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Alessandrea C. Quane sold 16,793 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $17.06, for a total transaction of $286,488.58. Following the completion of the sale, the executive vice president now directly owns 392,607 shares of the company’s stock, valued at approximately $6,697,875.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mario Schlosser sold 3,198 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $17.99, for a total transaction of $57,532.02. Following the completion of the transaction, the insider now directly owns 76,982 shares in the company, valued at $1,384,906.18. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 169,569 shares of company stock valued at $3,007,069 over the last ninety days. Company insiders own 25.11% of the company’s stock.

Hedge Funds Weigh In On Oscar Health

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Oscar Health by 2.4% during the first quarter. Vanguard Group Inc. now owns 14,582,762 shares of the company’s stock worth $216,846,000 after purchasing an additional 337,850 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Oscar Health by 153.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,978,152 shares of the company’s stock worth $59,156,000 after acquiring an additional 2,409,160 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Oscar Health by 31.7% during the 2nd quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company’s stock worth $61,478,000 after acquiring an additional 934,600 shares in the last quarter. First Light Asset Management LLC boosted its holdings in Oscar Health by 117.3% during the 1st quarter. First Light Asset Management LLC now owns 2,102,554 shares of the company’s stock valued at $31,265,000 after acquiring an additional 1,134,919 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Oscar Health by 32.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,046,046 shares of the company’s stock valued at $32,368,000 after acquiring an additional 507,009 shares in the last quarter. Hedge funds and other institutional investors own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.